Search / Trial NCT06235047

Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)

Launched by FEDERICO II UNIVERSITY · Jan 23, 2024

Trial Information

Current as of October 04, 2024

Completed

Keywords

C Hl >60y Liposomal Doxorubicin

Description

Classic Hodgkin lymphoma (c-HL) is a neoplasm that originates from B lymphocytes and represents 10% of all lymphomas. The most affected age group is between 20 and 30 years of age, with a second peak in the epidemiological distribution involving patients over 60 years of age. Elderly patients often present with already advanced disease stages and B symptoms. On the other hand, these patients often have multiple comorbidities and reduced fitness and this can limit the therapeutic possibilities with curative intent in terms of doses and adherence to the timing foreseen by the therapeutic pro...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * previously untreated, biopsy-proven c-HL
  • * Ann Arbor stage III or IV
  • * ECOG PS 0-3
  • * LVEF≥50% at echocardiographic assessment
  • * human immunodeficiency virus negativity.
  • * any GLS value
  • Exclusion Criteria:
  • * Ann Arbor stage I or II,
  • * concomitant major illnesses
  • * creatinine clearance \<30 ml/min
  • * serum transaminases more than three times the normal value
  • * total bilirubin \>3.4 mg/dl
  • * absolute neutrophil count \<500/mm 3
  • * hemoglobin level \<9 g/dL
  • * platelet count \<75 000/mm 3
  • * Myocardial infarction represented an exclusion only if diagnosed within 3 months prior to MVD start.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Naples, , Italy

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0